Corcept Therapeutics Inc (CORT): Revenue
$761.41M
Year ended 2025-12-31
$830.81M
Trailing 12 months to 2026-06-30
+23.7%
3-year compound annual growth
+16.6%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $761.41M | +12.8% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $675.04M | +39.9% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $482.38M | +20.0% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $401.86M | +9.8% | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | $365.98M | +3.4% | 2024-02-15, From 2021-01-01 |
| 2020-12-31 | $353.87M | +15.5% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $306.49M | +22.0% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $251.25M | +57.8% | 2021-02-23, From 2018-01-01 |
| 2017-12-31 | $159.20M | +95.8% | 2020-02-24, From 2017-01-01 |
| 2016-12-31 | $81.32M | n/a | 2019-02-26, From 2016-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $761.41M | +12.8% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $742.90M | -28.8% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $780.57M | +23.6% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $726.41M | +3.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $719.89M | -1.7% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $718.95M | +8.6% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $829.45M | n/m |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $677.56M | +60.1% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $673.00M | +20.2% |
Compare CORT, EBS, COLL, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗